References
- Crushable Glass Ampoules. James Alexander Corporation. [cited 2020 Sept 8]. Available at: https://www.james-alexander.com/pdf/glass-ampoules.pdf
- Asakura T, Seino H, Nozaki S, et al. Occurrence of coring in insulin vials and possibility of rubber piece contamination by self-injection. Yakugaku Zasshi. 2001;121(6):459–463.
- Preston ST, Hegadoren K. Glass contamination in parenterally administered medication. J Adv Nurs. 2004;48(3):266–270.
- Ampin. DigitalMuseum Marinmuseum. [cited 2020 Sept 8]. Available at: https://digitaltmuseum.se/011024819594/ampin
- Ravi A, Sadhna D, Nagpaal D, et al. Needle free injection technology: A complete insight. Int J Pharm Investig. 2015. DOI:https://doi.org/10.4103/2230-973X.167662.
- Jezek J, Darton NJ, Derham BK, et al. Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv. 2013;10(6):811–828.
- Ikesue H, Vermeulen LC, Hoke R, et al., Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. Am J Heal Pharm. 67(3): 223–226. 2010.
- HIGHRIGHTS OF PRESCRIBING INFORMATION. KYMRIAHTM. FDA. [cited 2020 Sept 8]. Available at: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert—KYMRIAH.pdf
- HIGHRIGHTS OF PRESCRIBING INFORMATION. YESCARTA®. FDA. [cited 2020 Sept 8]. Available at: https://www.fda.gov/media/108377/download
- HIGHRIGHTS OF PRESCRIBING INFORMATION. IMLYGIC®. FDA. [cited 2020 Sept 8]. Available at: https://www.fda.gov/media/94129/download
- HIGHRIGHTS OF PRESCRIBING INFORMATION. LUXTURNA®. FDA. [cited 2020 Sept 8]. Available at: https://www.fda.gov/media/109906/download
- HIGHRIGHTS OF PRESCRIBING INFORMATION. ZOLGENSMA®. FDA. [cited 2020 Sept 8]. Available at: https://www.fda.gov/media/126109/download
- Waters R, Urquhart L. World Preview 2019, Outlook to 2024. Eval Pharma. 2019:1–26.
- KEGG DRUG Database. [cited 2020 Sept 8]. Available at: https://www.kegg.jp/kegg/drug/drug_ja.html
- Nema S, Ludwig JD. Pharmaceutical Dosage Forms - Parenteral Medications Volume 1: formulation and Packaging. informa healthcare. CRC Press; 2016.
- Chow EJ, Kitaguchi B, Trier M. Effects of subzero temperature exposure and supercooling on glass vial breakage: risk management and other applications in cold chain distribution. PDA J Pharm Sci Technol. 2012. DOI:https://doi.org/10.5731/pdajpst.2012.00772
- Jiang G, Akers M, Jain M, et al. Mechanistic studies of glass vial breakage for frozen formulations. II. Vial breakage caused by amorphous protein formulations. PDA J Pharm Sci Technol. 2007;61(6):452-460.
- Zhao J, Lavalley V, Mangiagalli P, et al. Glass Delamination: a Comparison of the Inner Surface Performance of Vials and Pre-filled Syringes. Ageing Int. 2014;15:1398–1409.
- Reynolds G, Paskiet D. Glass delamination and breakage. Bioprocess Int. 2011. [cited 2020 Sept 8]. Available at: https://bioprocessintl.com/manufacturing/fill-finish/glass-delamination-and-breakage-324844/
- Srinivasan C, Ma Y, Liu Y, et al. Quality attributes and evaluation of pharmaceutical glass containers for parenterals. Int J Pharm. 2019. DOI:https://doi.org/10.1016/j.ijpharm.2019.118510.
- Subpart E–Control of Components and Drug Product Containers and Closures. Code of Federal Regulations, Title 21, Volume 4. Food and Drug Administration (FDA). 2019. [cited 2020 Sept 8]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211&showFR=1&subpartNode=21:4.0.1.1.11.5
- PMDA. The Japanese Pharmacopoeia. 17th Ed. 2011. Vol. 2014: 2319.
- Teska BM, Brake JM, Tronto GS, et al. Aggregation and Particle Formation of Therapeutic Proteins in Contact With a Novel Fluoropolymer Surface Versus Siliconized Surfaces: effects of Agitation in Vials and in Prefilled Syringes. J Pharm Sci. 2016;105(7):2053–2065.
- Gerhardt A, McGraw NR, Schwartz DK, et al. Protein aggregation and particle formation in prefilled glass syringes. J Pharm Sci. 2014;103(6):1601–1612.
- Li Y, Pan D, Nashine V, et al., Understanding Protein-Interface Interactions of a Fusion Protein at Silicone Oil-Water Interface Probed by Sum Frequency Generation Vibrational Spectroscopy. J Pharm Sci. 107(2): 682–689. 2018.
- Krayukhina E, Tsumoto K, Uchiyama S, et al. Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins. J Pharm Sci. 2015;104(2):527–535.
- Defante AP, Kalonia CK, Keegan E, et al. The Impact of the Metal Interface on the Stability and Quality of a Therapeutic Fusion Protein. Mol Pharm. 2020;17:569–578.
- Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking Subvisible Particles in Therapeutic Protein Products: gaps that may Compromise Product Quality. J Pharm Sci. 2009;98(4):1201–1205.
- Maruno T, Watanabe H, Yoneda S, et al. Sweeping of Adsorbed Therapeutic Protein on Prefillable Syringes Promotes Micron Aggregate Generation. J Pharm Sci. 2018;1–9.
- Hoehne M, Samuel F, Dong A, et al. Adsorption of monoclonal antibodies to glass microparticles. J Pharm Sci. 2011. DOI:https://doi.org/10.1002/jps.22275.
- Mahler HC, Müller R, Frieß W, et al. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm. 2005. DOI:https://doi.org/10.1016/j.ejpb.2004.12.004.
- Gerhardt A, McUmber AC, Nguyen BH, et al. Surfactant Effects on Particle Generation in Antibody Formulations in Pre-filled Syringes. J Pharm Sci. 2015;104(12):4056–4064.
- Torisu T, Maruno T, Hamaji Y, et al. Synergistic Effect of Cavitation and Agitation on Protein Aggregation. J Pharm Sci. 2017. DOI:https://doi.org/10.1016/j.xphs.2016.10.015.
- Torisu T, Maruno T, Yoneda S, et al. Friability Testing as a New Stress-Stability Assay for Biopharmaceuticals. J Pharm Sci. 2017;106(10):2966–2978.
- Iacocca RG, Toltl N, Allgeier M, et al. Factors affecting the chemical durability of glass used in the pharmaceutical industry. AAPS Pharm Sci Tech. 2010;11(3):1340–1349.
- Ditter D, Mahler HC, Gohlke L, et al. Impact of Vial Washing and Depyrogenation on Surface Properties and Delamination Risk of Glass Vials. Pharm Res. 2018;35(7):146.
- Iacocca RG, Allgeier M. Corrosive attack of glass by a pharmaceutical compound. J Mater Sci. 2007;42(3):801–811.
- BACON FR, RAGGON FC. Promotion of Attack on Glass and Silica by Citrate and Other Anions in Neutral Solution. J Am Ceram Soc. 1959;42(4):199–205.
- Ratnaswamy G, Hair A, Li G, et al. A case study of nondelamination glass dissolution resulting in visible particles: implications for neutral pH formulations. J Pharm Sci. 2014;103(4):1104–1114.
- Sloey C, Gleason C, Phillips J. Determining the delamination propensity of pharmaceutical glass vials using a direct stress method. PDA J Pharm Sci Technol. 2013. DOI:https://doi.org/10.5731/pdajpst.2013.00900
- Ditter D, Nieto A, Mahler HC, et al. Evaluation of Glass Delamination Risk in Pharmaceutical 10 mL/10R Vials. J Pharm Sci. 2018;107(2):624–637.
- General Chapter <1660> Evaluation of the Inner Surface Durability of Glass Containers Posted for Comment. USP. 2012. [cited 2020 Sept 8]. Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/c1660.pdf jfnjgj
- Valotta Rodrigues R, Puryear M, Sederstrom D, et al. Parameters Influencing Cavitation Within Vials Subjected to Drop Shock. Sci Rep. 2019;9(1):1–14.
- Wu H, Chisholm CF, Puryear M, et al., Container Surfaces Control Initiation of Cavitation and Resulting Particle Formation in Protein Formulations After Application of Mechanical Shock. J Pharm Sci. 2020;109(3): 1270–1280.
- Richter C, Lipperheide C, Lipke U, et al. Impact of extractables from rubber closures on protein stability under heat stress. Eur J Pharm Biopharm. 2018;130:22–29.
- Zdravkovic SA. Comparison of the Levels of Rubber Stopper-Related Organic Leachables in Commercially Available Vialed Liquid and Lyophilized Drug Products. Pharm Res. 2020;37(4):76.
- Rosenberg AS. Effects of protein aggregates: an immunologic perspective. Aaps J. 2006;8(3):E501–E507.
- van den Bemt BJF, Gettings L, Domańska B, et al., A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 26(1): 384–392. 2019.
- Ingle RG, Agarwal AS. Pre-filled syringe-a ready-to-use drug delivery system: A review. Expert Opin Drug Deliv. 2014;11(9):1391–1399.
- Li J, Cheng Y, Chen X, et al. Impact of electroviscous effect on viscosity in developing highly concentrated protein formulations: lessons from non-protein charged colloids. Int J Pharm X. 2019;1:100002.
- Schermeyer MT, Wöll AK, Kokke B, et al. Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stability. MAbs. 2017;9(7):1169–1185.
- De Bardi M, Müller R, Grünzweig C, et al. On the needle clogging of staked-in-needle pre-filled syringes: mechanism of liquid entering the needle and solidification process. Eur J Pharm Biopharm. 2018;128:272–281.
- Krayukhina E, Fukuhara A, Uchiyama S. Assessment of the Injection Performance of a Tapered Needle for Use in Prefilled Biopharmaceutical Products. J Pharm Sci. 2020;109(1):515–523.
- Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94(4):918–927.
- Werner BP, Schöneich C, Winter G. Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins. J Pharm Sci. 2019;108(3):1148–1160.
- Baldwin RN. Contamination of Insulin by Silicone Oil: a Potential Hazard of Plastic Insulin Syringes. Diabet Med. 1988;5(8):789–790.
- Majumdar S, Ford BM, Mar KD, et al. Evaluation of the effect of syringe surfaces on protein formulations. J Pharm Sci. 2012;100(7):2563–2573.
- Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–1467.
- Bee JS, Nelson SA, Freund E, et al. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci. 2009;98(9):3290–3301.
- Liu W, Swift R, Torraca G, et al. Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes. PDA J Pharm Sci Technol. 2010;64(1):11–19.
- <661> Plastic Packaging Systems and Their Materials of Construction. FDA. 2017. [cited 2020 Sept 8]. Available at: https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/661_rb_notice.pdf
- Amano M, Kiichi F, Uchiyama S. Suppression of Methionine Oxidation of a Pharmaceutical Antibody Stored in a Polymer-Based Syringe. J Pharm Sci. 2016;105(2):623–629.
- Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422–430.
- Pan H, Chen K, Chu L, et al. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 2009;18(2):424–433.
- Wang W, Vlasak J, Li Y, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48(6–7):860–866.
- Nakamura K, Abe Y, Kiminami H, et al. A strategy for the prevention of protein oxidation by drug product in polymer-based syringes. PDA J Pharm Sci Technol. 2015;69(1):88–95.
- Shimizu S, Smith DJ. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys. 2004;121(2):1148–1154.
- He F, Woods CE, Litowski JR, et al. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res. 2011;28:1552–1560.
- Sedlák E, Stagg L, Wittung-Stafshede P. Effect of Hofmeister ions on protein thermal stability: roles of ion hydration and peptide groups? Arch Biochem Biophys. 2008;479(1):69–73.
- Bye JW, Falconer RJ. Thermal stability of lysozyme as a function of ion concentration: A reappraisal of the relationship between the Hofmeister series and protein stability. Protein Sci. 2013;22(11):1563–1570.
- Ionova Y, Wilson L. Biologic excipients: importance of clinical awareness of inactive ingredients. PLoS One. 2020;15(6):1–13.
- Kerwin BA. Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: structure and Degradation Pathways. Int J Pharm. 2008;97:12–17.
- Ha E, Wang WEI, Wang YJ. Peroxide Formation in Polysorbate 80 and Protein Stability. Int J Res. 2002;91:2252–2264.
- Dwivedi M, Blech M, Presser I, et al. Polysorbate degradation in biotherapeutic formulations: identification and discussion of current root causes. Int J Pharm. 2018;552(1–2):422–436.
- Schaut RA, Peanasky JS, Demartino SE, et al. A new glass option for parenteral packaging. PDA J Pharm Sci Technol. 2014;68(5):527–534.
- Schaut RA, Hoff KC, Demartino SE, et al. Enhancing patient safety through the use of a pharmaceutical glass designed to prevent cracked containers. PDA J Pharm Sci Technol. 2017;71(6):511–528.
- Zarour-Shalev EH, Ovadia Y, Tuchmay O, et al. Filtration of Glass Delamination Particles with West Pharmaceutical Vial Adapters. PDA J Pharm Sci Technol. 2015;69(6):669–676.
- Weikart CM, Pantano CG, Shallenberger JR. Performance stability of silicone oxide-coated plastic parenteral vials. PDA J Pharm Sci Technol. 2017;71(4):317–327.
- Vieregg JR, Martin SJ, Breeland AP, et al. Inhibiting sterilization-induced oxidation of large molecule therapeutics packaged in plastic parenteral vials. PDA J Pharm Sci Technol. 2018;72(1):35–43.
- Höger K, Becherer T, Qiang W, et al. Polyglycerol coatings of glass vials for protein resistance. Eur J Pharm Biopharm. 2013;85(3 Pt A):756–764.
- Funke S, Matilainen J, Nalenz H, et al. Silicone Migration From Baked-on Silicone Layers. Particle Characterization in Placebo and Protein Solutions. J Pharm Sci. 2016;105(12):3520–3531.
- Krayukhina E, Yokoyama M, Hayashihara KK, et al. An Assessment of the Ability of Submicron- and Micron-Size Silicone Oil Droplets in Dropped Prefillable Syringes to Invoke Early- and Late-Stage Immune Responses. J Pharm Sci. 2019;108(7):2278–2287.
- Uchino T, Miyazaki Y, Yamazaki T, et al. Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice. J Pharm Pharmacol. 2017;69(10):1341–1351.
- Silicone-Free Plungers To Enable Delivery Of Complex, Sensitive Biologics. W. L. Gore & Associates, Inc; 2016. Available at: https://www.gore.com/system/files/2019-11/PB8759_Rev3_MA_US_SEP19-e.pdf
- SCHOTT teams up with GORE to introduce world’s first silicone-free glass syringe system. SCHOTT AG. 2019. [cited 2020 Sept 8]. Available at: https://www.schott.com/english/news/press.html?NID=com5685
- Kiminami H, Takeuchi K, Nakamura K, et al. Low Leachable Container System Consisting of a Polymer-Based Syringe with Chlorinated Isoprene Isobutene Rubber Plunger Stopper. PDA J Pharm Sci Technol. 2015;69(6):713–724.
- Release P. Terumo Announces European Launch of Biosimilar Using Terumo ’ s PLAJEX TM Pre-fillable Syringes. Terumo Corporation. 2018. [cited 2020 Sept 8]. Available at: https://www.terumo-europe.com/en-emea/news/terumo-announces-european-launch-of-biosimilar-using-terumo%E2%80%99s-plajex%E2%84%A2-pre-fillable-syringes
- HIGHRIGHTS OF PRESCRIBING INFORMATION. LUPRON DEPOT®. FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020708s035lbl.pdf Cited 2020 Sept 8
- Jayaprakash V, Costalonga M, Dhulipala S, et al. Enhancing the Injectability of High Concentration Drug Formulations Using Core Annular Flows. Adv Healthc Mater. 2020;2001022:1–7.
- Petersen C. Prefillable syringe developments to meet biotech drug needs. ONdrugDelivery. 2018;2018:18–22.
- Small Needlestick — large Risk. Schreiner MediPharm. 2010. [cited 2020 Sept 8]. Available at: https://m.needle-trap.com/fileadmin/user_upload/downloads/Whitepaper_SMP_NeedleTrap_e.pdf
- Quinn HL, Kearney MC, Courtenay AJ, et al. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv. 2014;11(11):1769–1780.
- Hung IFN, Levin Y, To KKW, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012;30(45):6427–6435.
- NanoPass Technologies Ltd., [cited 2020 Oct 12]. Available at: https://www.nanopass.com/.
- Arakane R, Nakatani H, Fujisaki E, et al. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. Vaccine. 2015;33(46):6340–6350.
- Waghule T, Singhvi G, Dubey SK, et al. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother. 2019;109:1249–1258.
- Ita K. Transdermal delivery of drugs with microneedles—potential and challenges. Pharmaceutics. 2015;7(3):90–105.
- Pyro-drive Jet Injector Actranza™ lab. DAICEL CORPORATION. [cited 2020 Oct 12]. Available at: https://www.daicel.com/en/business/new-solution/actranza/
- PharmaJetⓇ. [cited 2020 Oct 12]. Available at: https://pharmajet.com/.